Related Experiment Videos
One-year stability of resin-dentin bonds created with a hydrophobic ethanol-wet bonding technique
Fernanda T Sadek1, Carina S Castellan, Roberto R Braga
1Department of Dental Materials, School of Dentistry, University of São Paulo, São Paulo, SP, Brazil.
Unlabelled:
Dentin bonding performed with hydrophobic resins using ethanol-wet bonding should be less susceptible to degradation but this hypothesis has never been validated.
Objectives:
This in vitro study evaluated stability of resin-dentin bonds created with an experimental three-step BisGMA/TEGDMA hydrophobic adhesive or a three-step hydrophilic adhesive after one year of accelerated aging in artificial saliva.
Methods:
Flat surfaces in mid-coronal dentin were obtained from 45 sound human molars and randomly divided into three groups (n=15): an experimental three-step BisGMA/TEGDMA hydrophobic adhesive applied to ethanol (ethanol-wet bonding-GI) or water-saturated dentin (water-wet bonding-GII) and Adper Scotchbond Multi-Purpose [MP-GIII] applied, according to manufacturer instructions, to water-saturated dentin. Resin composite crowns were incrementally formed and light-cured to approximately 5mm in height. Bonded specimens were stored in artificial saliva at 37 degrees C for 24h and sectioned into sticks. They were subjected to microtensile bond test and TEM analysis immediately and after one year. Data were analyzed with two-way ANOVA and Tukey tests.
Results:
MP exhibited significant reduction in microtensile bond strength after aging (24h: 40.6+/-2.5(a); one year: 27.5+/-3.3(b); in MPa). Hybrid layer degradation was evident in all specimens examined by TEM. The hydrophobic adhesive with ethanol-wet bonding preserved bond strength (24h: 43.7+/-7.4(a); one year: 39.8+/-2.7(a)) and hybrid layer integrity, with the latter demonstrating intact collagen fibrils and wide interfibrillar spaces.
Significance:
Coaxing hydrophobic resins into acid-etched dentin using ethanol-wet bonding preserves resin-dentin bond integrity without the adjunctive use of MMPs inhibitors and warrants further biocompatibility and patient safety's studies and clinical testing.